On May 18, 2026 SEED Therapeutics, Inc. ("SEED"), a clinical-stage biotechnology company developing rationally designed molecular glue degraders, reported that it will present a poster on ST-01156, its orally administered, selective RBM39 molecular glue degrader currently in a first-in-human Phase 1 study, at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 through June 2 in Chicago, IL. The poster will describe the trial design and preclinical rationale for the ongoing Phase 1 study of ST-01156 in patients with advanced solid malignancies, with a focus on RBM39-dependent cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"RBM39 is a compelling oncology target whose therapeutic potential has been constrained by prior chemical matter. ST-01156 was designed as an oral, selective, brain-penetrant molecular glue degrader to test that hypothesis with the pharmacologic profile required for patients with advanced solid tumors. This Phase 1 study is structured to rigorously characterize its safety, pharmacology, and early signals of activity in patients with RBM39-dependent cancers, including those who have exhausted standard treatment options," said Eric K. Rowinsky, M.D., clinical and medical lead at SEED and presenting author of the poster.
Presentation details are as follows:
Title: First-in-Human Clinical Evaluation of ST-01156, an Optimized and Selective Degrader of RNA-Binding Motif 39 (RBM39): A Phase 1 Study in Advanced Solid Malignancies with a Focus on RBM39-Dependent Cancers
Presenter/Authors: Eric K. Rowinsky, Gregory M. Cote, George D. Demetri, Robert G. Maki, Suzanne George, Daneng Li, Alain C. Mita, Monica M. Mita, Jordi Rodon Ahnert, Dan Lu, Dong Liu, Lan Huang, James Tonra
Presentation Time: Saturday, May 30, 2026, from 1:30 p.m. to 4:30 p.m. CDT
Location: McCormick Place, Chicago, IL
Session: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
Abstract Number: TPS3164
Poster Board Number: 296b
(Press release, Seed Therapeutics, MAY 18, 2026, View Source [SID1234665851])